WO2020218518A1 - 医薬製剤およびその製造方法 - Google Patents
医薬製剤およびその製造方法 Download PDFInfo
- Publication number
- WO2020218518A1 WO2020218518A1 PCT/JP2020/017711 JP2020017711W WO2020218518A1 WO 2020218518 A1 WO2020218518 A1 WO 2020218518A1 JP 2020017711 W JP2020017711 W JP 2020017711W WO 2020218518 A1 WO2020218518 A1 WO 2020218518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical preparation
- nuclear particle
- particle component
- nuclear
- preparation according
- Prior art date
Links
- 0 *=C(c1ccncc1)Nc1cc(F)ccc1N1CCCCC1 Chemical compound *=C(c1ccncc1)Nc1cc(F)ccc1N1CCCCC1 0.000 description 3
- VRKZHYSJZOUICG-UHFFFAOYSA-N Fc(cc1NC(c2ccncc2)=S)ccc1N1CCCCC1 Chemical compound Fc(cc1NC(c2ccncc2)=S)ccc1N1CCCCC1 VRKZHYSJZOUICG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Definitions
- the present invention relates to a pharmaceutical preparation and a method for producing the same.
- aniline derivatives such as N- [5-fluoro-2- (1-piperidinyl) phenyl] isonicotinthioamide, which is a CDK9 inhibitor, can be used as an antiviral drug that suppresses virus production.
- Non-Patent Documents 1 to 4 N- [5-fluoro-2- (1-piperidinyl) phenyl] isonicotinthioamide, which is a CDK9 inhibitor
- CDK9 inhibitors have low solubility in water, it is difficult to dissolve an effective amount of the inhibitor contained in the preparation to show sufficient efficacy.
- soft capsules are widely used as solid preparations that can contain a therapeutically effective amount of a poorly water-soluble drug (for example, Patent Document 1).
- a poorly water-soluble drug for example, Patent Document 1
- soft capsules may have a larger diameter than other solid preparations such as tablets, there is a problem that they are difficult to take for children and the elderly with low swallowing ability, patients with poor swallowing ability, and the like. ..
- soft capsules have a risk of leaking easily depending on the manufacturing method due to their nature.
- soft capsules are soft and easily deformed, the presence or absence of deformation must be inspected visually by humans or using a dedicated inspection machine. From the viewpoint of manufacturing cost, tablets, etc. There is a problem that it is expensive compared to the solid preparation of.
- a drug preparation containing granules containing a combination of a drug and a solubilizer is known, and it is known that a surfactant can be used as the solubilizer and the granules can be coated.
- a surfactant has adhesiveness and adhesiveness and lowers the fluidity, there is a problem that the blending amount is limited when it is used for the preparation of pharmaceutical preparations such as tablets.
- solubilizing substance such as a surfactant
- a solubilizing substance such as a surfactant
- a poorly water-soluble drug such as a CDK9 inhibitor
- sufficient fluidity is obtained in the formulation process. Therefore, it is difficult to formulate a therapeutically effective amount of a drug in the formulation of tablets and the like whose low fluidity affects the formulation.
- a pharmaceutical preparation comprising a nuclear particle containing a drug (CDK9 inhibitor) together with a nuclear particle component having a specific shape and a coating layer covering the nuclear particle was prepared. It has been found that a pharmaceutical preparation can contain a large amount of a surfactant and a drug and has excellent fluidity. The present invention is based on such findings.
- the present invention includes the following inventions.
- a pharmaceutical preparation in the form of granules comprising nuclear particles and a coating layer covering the nuclear particles.
- the nuclear particle comprises a drug, a first nuclear particle component, a second nuclear particle component and a surfactant.
- the drug has the following general formula (I) [W represents S or O in the formula] Aniline derivative represented by, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- the first nuclear particle component is at least one crystalline cellulose having a shape selected from needle-like and substantially columnar.
- the pharmaceutical formulation, wherein the second nuclear particle component is at least one pharmaceutically acceptable additive that is substantially spherical.
- the drug is represented by the following formula (Ia).
- the ratio of the 50% particle diameter (D50) of the volume distribution standard of the first nuclear particle component to the 50% particle diameter (D50) of the volume distribution standard of the second nuclear particle component is 1: 1.1.
- the pharmaceutical preparation according to any one of [1] to [7], wherein the difference in the average aspect ratio between the first nuclear particle component and the second nuclear particle component is 0.5 or more.
- the pharmaceutical preparation according to any one of [1] to [8], wherein the second nuclear particle component comprises at least two different components.
- the pharmaceutical preparation according to any one of [1] to [9], wherein the mass ratio of the first nuclear particle component to the second nuclear particle component is 1: 1 to 1:10.
- the mass ratio of the total mass of the first nuclear particle component and the second nuclear particle component to the mass of the surfactant is 1: 0.01 to 1: 0.6, [1].
- the pharmaceutical preparation according to any one of [1] to [11], wherein the mass ratio of the surfactant to the drug is 1: 0.1 to 1:10.
- the mass ratio of the total mass of the first nuclear particle component and the second nuclear particle component to the mass of the coating layer is 1: 0.05 to 1: 0.3, [1] to The pharmaceutical preparation according to any one of [12].
- the second nuclear particle component is any of [1] to [13], wherein the second nuclear particle component is at least one pharmaceutically acceptable additive selected from the group consisting of saccharides and inorganic compounds. Pharmaceutical preparations.
- the second nuclear particle component is glucose, fructose, lactose, lactose hydrate, sucrose, sucrose, compressed sugar, refined powdered sugar, ammonium alginate, starch, potato starch, wheat starch, corn starch, rice.
- the water-soluble coating agent is polyethylene glycol, methyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methacrylic acid copolymer, vinyl pyridine copolymer, alkyl vinyl pyridine copolymer, amino cellulose derivative, diethyl aminoethyl methacrylate, polyvinyl acetal.
- [21] The pharmaceutical preparation according to any one of [1] to [20], wherein the degree of cohesion of the pharmaceutical preparation is 70% or less.
- a preparation comprising the pharmaceutical preparation according to any one of [1] to [23] and having a dosage form selected from the group consisting of granules, tablets, capsules, powders and pills.
- a method for producing a pharmaceutical preparation in the form of granules comprising nuclear particles and a coating layer covering the nuclear particles.
- C) The nuclear particle mixture obtained in step (a) and the mixed solution obtained in step (b) are brought into contact with each other to bring the first nuclear particle component, the second nuclear particle component, the drug and the surfactant.
- the process of obtaining nuclear particles containing D) Including the step of coating the nuclear particles obtained in step (c) to obtain a pharmaceutical preparation.
- the drug has the following general formula (I) [In the formula, W represents S or O] Aniline derivative represented by, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- the first nuclear particle component is at least one crystalline cellulose having a shape selected from needle-like and substantially columnar.
- the production method, wherein the second nuclear particle component is at least one pharmaceutically acceptable additive that is substantially spherical.
- the drug is represented by the following formula (Ia).
- the production method according to [25] which is an aniline derivative represented by the above, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- a method for producing a tablet which comprises a step of tableting and molding the pharmaceutical preparation according to any one of [1] to [23] to obtain a tablet.
- a method for producing a capsule which comprises a step of encapsulating the pharmaceutical preparation according to any one of [1] to [23].
- the present invention it is possible to provide a pharmaceutical preparation in the form of granules containing a therapeutically effective amount of a drug and having excellent fluidity that can withstand actual production. Further, according to the present invention, it is possible to suppress aggregation that causes a decrease in the fluidity of the pharmaceutical preparation. As a result, excellent fluidity is realized in the pharmaceutical preparation, so that a large amount of the poorly water-soluble component can be blended even in the pharmaceutical preparation such as tablets whose formulation is hindered by the decrease in fluidity. Furthermore, the pharmaceutical preparation of the present invention can prevent the surfactant contained in the nuclear particles from leaking to the surface of the pharmaceutical preparation even when stored for a long period of time.
- FIG. 1A and 1B are electron micrographs of the first nuclear particle component (needle-shaped crystalline cellulose).
- FIG. 1A is an electron micrograph of acicular crystalline cellulose (CEOLUS KG-1000)
- FIG. 1B is an electron micrograph of acicular crystalline cellulose (CEOLUS UF-702).
- FIG. 2 is an electron micrograph of the second nuclear particle component (substantially spherical particles: lactose hydrate).
- FIG. 3 is an electron micrograph of the second nuclear particle component (substantially spherical particles: corn starch).
- the pharmaceutical preparation of the present invention is a pharmaceutical preparation in the form of granules comprising nuclear particles and a coating layer covering the nuclear particles.
- a pharmaceutical preparation in the form of granules comprising nuclear particles and a coating layer covering the nuclear particles.
- each of the nuclear particles and the coating layer will be described.
- the nuclear particle comprises a drug, a first nuclear particle component, a second nuclear particle component and a surfactant, and the first nuclear particle component is a needle-like and / or substantially columnar crystalline cellulose (hereinafter, simply “. It may be referred to as “needle-shaped crystalline cellulose”), and the second nuclear particle component is at least one pharmaceutically acceptable additive having a substantially spherical shape.
- the nuclear particle contains a first nuclear particle component and a second nuclear particle component having significantly different shapes, many voids are formed between the first nuclear particle component and the second nuclear particle component. Can be done. As a result, a large surface area can be contained in the nuclear particles, so that the nuclear particles can contain a large amount of the liquid component. Then, since the nuclear particles can contain a large amount of a surfactant used as a solubilizer as a liquid component, a poorly water-soluble drug can be dissolved or suspended. Without being bound by theory, it is believed that such a mechanism makes it possible to produce pharmaceutical preparations containing a large amount of sparingly soluble drug in the nuclear particles.
- the first nuclear particle component used for the nuclear particles is acicular crystalline cellulose.
- the acicular crystalline cellulose which is the first nuclear particle component used in the present invention is derived from the crystalline cellulose which can be added in the preparation of a pharmaceutical preparation.
- the needle-shaped crystalline cellulose may contain a sufficient proportion of needle-shaped and / or substantially columnar crystals so that the effects of the present invention can be exhibited.
- the lower limit of the proportion of acicular and / or substantially columnar crystalline cellulose in the first nuclear particle component is not particularly limited, but the number of crystals (particles) is preferably 60%, more preferably 70%, and even more. It is preferably 80%.
- the upper limit can be, for example, 100%, 98%, 95%, 90% or the like.
- the range of the proportion of acicular and / or substantially columnar crystalline cellulose in the first nuclear particle component is not particularly limited, but the number of crystals (particles) is preferably 60 to 100%, more preferably 70 to 100%. , Even more preferably 80 to 100%.
- "needle-shaped crystalline cellulose” has a remarkable difference in vertical and horizontal lengths in a cross section in the long axis direction of crystalline cellulose on an image (a shape transferred to a plane) measured by an electron microscope. Crystalline cellulose.
- the remarkable difference in the vertical and horizontal lengths can be expressed by, for example, the aspect ratio.
- the average aspect ratio of the first nuclear particle component is not particularly limited as long as the effect of the present invention is exhibited, but it is larger than the average aspect ratio of the second nuclear particle component, and the lower limit value is It is preferably 1.8, more preferably 2.2, and even more preferably 2.5.
- the upper limit of the average aspect ratio of the first nuclear particle component is not particularly limited as long as the effect of the present invention is exhibited, and may be, for example, 10, 8 or the like.
- the range of the average aspect ratio of the first nuclear particle component is not particularly limited, but is preferably 1.8 to 10, more preferably 2.2 to 10, and even more preferably 2.5 to 10. ..
- the “aspect ratio” of the nuclear particle component means the value (major axis / minor axis) of the ratio of the major axis to the minor axis of the nuclear particle component in the particle image analysis using an electron microscope.
- the “average aspect ratio” of the nuclear particle component is the aspect ratio of 10 or more nuclear particle components selected arbitrarily, and the aspect ratio of the upper 10% and lower 10% of the aspect ratio values. It means the average value of the aspect ratios of the nuclear particle components excluding the ratio value.
- the amount of the first nuclear particle component is not particularly limited as long as the effect of the present invention is exhibited, but is preferably 5 to 50% by mass with respect to the total mass of the pharmaceutical preparation.
- the second nuclear particle component used for the nuclear particle is a substantially spherical pharmaceutically acceptable additive.
- substantially spherical refers to a shape that approximates a spherical shape with no significant difference in length and width on an image measured by an electron microscope (shape transferred to a plane), and is needle-shaped and. Does not include a substantially columnar shape. Therefore, according to one embodiment, the second nuclear particle component is a non-needle and non-columnar pharmaceutically acceptable additive.
- Approximately spherical does not necessarily mean that the image measured by an electron microscope is a perfect spherical shape, for example, a distorted spherical shape, an ellipsoidal shape, a polyhedral shape (including a cube shape), or a polyhedral shape with rounded corners. It may be.
- the average aspect ratio of the second nuclear particle component is smaller than the average aspect ratio of the first nuclear particle component, preferably 1.0 to 1.65, more preferably 1.0 to 1.5, and more. It is even more preferably 1.0 to 1.3, and even more preferably 1.0 to 1.2.
- the aspect ratio of the nuclear particle component and the average aspect ratio of the nuclear particle component are the same as those defined for the first nuclear particle component, respectively.
- the amount of the second nuclear particle component in the pharmaceutical preparation of the present invention is not particularly limited as long as the effect of the present invention is exhibited, but is preferably 30 to 90% by mass with respect to the total mass of the pharmaceutical preparation.
- the particle size of the second nuclear particle component is not particularly limited as long as the effect of the present invention is exhibited, but the 50% particle size (D50) of the volume distribution standard of the second nuclear particle component is the first nuclear particle.
- Ratio of component volume distribution standard to 50% particle size (D50) (1st nuclear particle component volume distribution standard 50% particle size (D50): 2nd nuclear particle component volume distribution standard 50% particle size (D50)) is preferably 1: 1.1 or less, more preferably 1: 0.8 or less, even more preferably 1: 0.5 or less, and even more preferably 1: 0.1 or less. It is adjusted to be.
- the second nuclear particle component one kind of component may be used alone, or two or more kinds of components may be used in combination, but preferably, the 50% particle diameter (D50) based on the volume distribution is different. Used in combination with seeds or higher components.
- the 50% particle diameter (D50) of each component based on the volume distribution is different.
- the 50% particle diameter (D50) of the volume distribution standard of the nuclear particle component is the total mass of each component constituting the nuclear particle component.
- the mass ratio is calculated, the product of the ratio and the 50% particle diameter (D50) based on the volume distribution is calculated for each component, and the product is calculated as the sum of the products.
- the nuclear particle component contains two components A and B, the masses of the components A and B are a and b, respectively, and the 50% particle diameter (D50) of the volume distribution reference of A and B is D50 A and, respectively.
- the 50% particle diameter (D50) based on the volume distribution of the nuclear particle component is calculated by the following formula: ..
- the component constituting the second nuclear particle component is not particularly limited as long as it is a pharmaceutically acceptable component, and examples thereof include sugars (including sugars, sugar hydrates, sugar alcohols, etc.), inorganic compounds, and the like. ..
- the sugar is not particularly limited, and examples thereof include monosaccharides such as glucose, disaccharides such as lactose and sucrose, and polysaccharides such as starch.
- monosaccharides such as glucose
- disaccharides such as lactose and sucrose
- polysaccharides such as starch.
- starch include potato starch, wheat starch, corn starch, rice starch and the like.
- corn starch is preferably used as the sugar.
- the sugar hydrate is not particularly limited, and examples thereof include any of the above-mentioned sugar hydrates, and lactose hydrate is preferably used.
- the sugar alcohol is not particularly limited, and examples thereof include sugar alcohols derived from any sugar, and mannitol or sorbitol is preferably used.
- the inorganic compound is not particularly limited, and examples thereof include phosphates such as anhydrous calcium phosphate.
- the first nuclear particle component has a larger average aspect ratio than the second nuclear particle component, and the difference between the average aspect ratios of the first and second nuclear particle components is large.
- the difference in the average aspect ratios of the first and second nuclear particle components is preferably 0.5. As mentioned above, it is more preferably 0.6 or more, and even more preferably 0.7 or more.
- the difference between the firmness density and the loose bulk density (hardness density-loose bulk density) of the mixture of the first and second nuclear particle components (nuclear particle mixture) is particularly limited as long as the effect of the present invention is exhibited.
- the lower limit is preferably 0.15, more preferably 0.16, even more preferably 0.17
- the upper limit is preferably 0.25, more preferably 0.24, even more preferably. Is 0.23
- the range is preferably 0.15 to 0.25, more preferably 0.16 to 0.24, and even more preferably 0.17 to 0.23.
- the firmness density and the loose bulk density can be measured using, for example, a commercially available powder property evaluation device (Powder Tester (registered trademark) PT-R, manufactured by Hosokawa Micron Co., Ltd.).
- a powder tester is used to put the nuclear particle mixture into a cylindrical container of the same size as the measurement container of the bulk density and tap density measurement method 3 described in the 17th revised Japanese Pharmacy.
- the bulk density (loose bulk density) in a loosely filled state is measured by uniformly supplying the particles from above through a sieve and weighing the top surface.
- an auxiliary cylinder is fitted on the container, a mixture of nuclear particles is added up to the upper edge, and tapping is performed 180 times.
- the auxiliary cylinder is removed, the nuclear particle mixture is ground and weighed on the upper surface of the container, and the bulk density (hard bulk density) in the case of tight packing after tapping is measured.
- the diameters (particle diameters) of the particles constituting the first and second nuclear particle components are not particularly limited as long as the effects of the present invention are exhibited, but the first nuclear particle components are 50% of the volume distribution standard.
- the particle size (D50) is preferably 50 to 200 ⁇ m, more preferably 60 to 150 ⁇ m, and even more preferably 70 to 100 ⁇ m.
- the volume distribution-based 50% particle diameter (D50) of the second nuclear particle component is preferably 1 to 300 ⁇ m, more preferably 5 to 200 ⁇ m, and even more preferably 10 to 150 ⁇ m.
- the diameter of the particles constituting the nuclear particle component in the present invention and the 50% particle diameter based on the volume distribution are both measured by a laser diffraction method (measurement) using, for example, a commercially available particle size distribution meter (for example, Mastersizer3000, manufactured by Spectris). Method: Dry method, scattering intensity: 1% or more, light scattering model: Mie scattering theory).
- the volume-based 50% particle size (D50) is the volume that is 50% of the cumulative volume distribution curve with the total volume as 100% in the volume-based particle size distribution measured by the laser diffraction method. It means the particle size.
- the total mass of the first and second nuclear particle components is not particularly limited as long as the effects of the present invention are exhibited, but is, for example, 20 to 90% by weight with respect to the total mass of the pharmaceutical preparation.
- the mass ratio of the first nuclear particle component to the second nuclear particle component is not particularly limited as long as the effect of the present invention is exhibited. However, for example, it is 1: 1 to 1:10.
- the pharmaceutical formulation of the present invention comprises a surfactant in which the drug can be dissolved or suspended in the nuclear particles.
- the surfactant is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include cationic surfactants, anionic surfactants, amphoteric surfactants, and nonionic surfactants. Can be used.
- the cationic surfactant include a primary amine salt, an alkyltrimethylammonium salt, an alkylpyridinium salt, an alkylpolyoxyethylene amine and the like.
- anionic surfactant examples include fatty acid salts, rosinates, alkylpolyoxyethylene sulfates, ⁇ -olefin sulfonates, alkylnaphthalene sulfonates, lignin sulfonates, alkyl phosphates and the like. Be done.
- amphoteric surfactant examples include N-alkyl ⁇ -aminopropionic acid, N-alkyl sulfobetaine, N-alkyl hydroxy sulfobetaine, lecithin and the like.
- nonionic surfactant examples include alkyl polyoxyethylene ether, polyoxyethylene fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester and the like.
- the surfactant is preferably a nonionic surfactant, more preferably polysorbate, and even more preferably polysorbate 80.
- One of these surfactants may be used alone, or two or more of these surfactants may be used in combination. Further, the surfactant may be used by dissolving it in water, alcohol or the like, for example.
- the amount of the surfactant is not particularly limited as long as the effect of the present invention is exhibited, but the lower limit is preferable as the mass ratio to the total amount of the nuclear particle components (total mass of the nuclear particle components: mass of the surfactant). Is 1: 0.001, more preferably 1: 0.01.
- the upper limit is not particularly limited, but is preferably 1: 0.6, more preferably 1: 0.4, and even more preferably 1: 0.3.
- the range of the mass ratio of the surfactant to the total amount of the nuclear particle components is not particularly limited, but is preferably 1: 0.001 to 1: 0.6, more preferably 1: 0.01 to 1: 0. 4, even more preferably 1: 0.01 to 1: 0.3.
- the pharmaceutical preparation of the present invention has the following general formula (I) in the nucleus.
- W represents S or O in the formula
- It comprises an aniline derivative represented by, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- the drug is preferably present in a state of being dissolved or suspended in the above-mentioned surfactant (hereinafter, may be referred to as "mixed solution”).
- solvent or suspension also includes a state in which a part of a drug is dissolved and the other part is suspended.
- the pharmaceutical preparation of the present invention may contain other drugs in addition to the above drugs.
- examples of other drugs include antiviral agents, anti-inflammatory agents, immunity enhancers and the like.
- the amount of the drug in the pharmaceutical preparation of the present invention is not particularly limited as long as the pharmaceutical preparation of the present invention exerts a desired effect, but as a mass ratio to the total amount of the nuclear particle components (mass of the drug: total mass of the nuclear particle components).
- the lower limit is preferably 0.01: 1, more preferably 0.02: 1, and even more preferably 0.03: 1.
- the upper limit is not particularly limited, but is preferably 0.5: 1, more preferably 0.2: 1.
- the range of the mass ratio of the drug to the total amount of the nuclear particle components is not particularly limited, but is preferably 0.01: 1 to 0.5: 1, more preferably 0.02: 1 to 0.5: 1. Even more preferably, it is 0.03: 1 to 0.2: 1.
- the amount of the drug in the pharmaceutical preparation of the present invention is not particularly limited as long as the pharmaceutical preparation of the present invention exerts a desired effect, but is the lower limit as the mass ratio to the surfactant (mass of drug: mass of surfactant).
- the value is preferably 0.05: 1, more preferably 0.1: 1, and even more preferably 0.5: 1.
- the upper limit is not particularly limited, but is preferably 5: 1, more preferably 3: 1.
- the range of the mass ratio of the drug to the surfactant is not particularly limited, but is preferably 0.05: 1 to 5: 1, more preferably 0.1: 1 to 5: 1, and even more preferably 0. It is 5: 1 to 3: 1.
- the degree of cohesion of nuclear particles in the pharmaceutical preparation of the present invention is not particularly limited, but is preferably 90% or less, more preferably 70% or less, and even more preferably 50% or less.
- the degree of cohesion can be measured using a commercially available powder property evaluation device.
- the powder property evaluation device include Powder Tester (registered trademark) PT-R (manufactured by Hosokawa Micron Co., Ltd.).
- the measurement conditions are as follows, for example. Opening of mesh: (upper) 710 ⁇ m, (middle) 355 ⁇ m, (lower) 250 ⁇ m Sampling volume: 2g or 3g Vibration time: 119 seconds
- the coating layer can coat the nuclear particles and prevent the surfactant or drug contained in the nuclear particles from leaking to the surface of the pharmaceutical preparation. As a result of suppressing the leakage of the surfactant by the coating layer, the aggregation of the pharmaceutical preparation can be suppressed, and the decrease in the fluidity of the pharmaceutical preparation can be suppressed.
- the components constituting the coating layer are not particularly limited, and examples thereof include water-soluble coating agents.
- the water-soluble coating agent one type may be used alone, or two or more types may be used in combination.
- the water-soluble coating agent preferably comprises at least one component selected from polyalkylene glycols and polysaccharides or derivatives thereof.
- the polysaccharide or its derivative is preferably a cellulose derivative, and examples thereof include methyl cellulose, hydroxymethyl cellulose, and hydroxypropyl methyl cellulose.
- a cellulose derivative examples thereof include methyl cellulose, hydroxymethyl cellulose, and hydroxypropyl methyl cellulose.
- One type of cellulose derivative may be used alone, or two or more types may be used in combination.
- examples of the polyalkylene glycol include polyethylene glycol and the like.
- the coating agent used for the coating layer includes hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methacrylic acid copolymer, vinyl pyridine copolymer, alkyl vinyl pyridine copolymer, amino cellulose derivative, diethyl aminoethyl.
- Methacrylate polyvinyl acetal diethylaminoacetate, dimethylaminoethyl methacrylate-methacrylate copolymer, cellulose acetate-N, N-di-n-butylhydroxylpropyl ether, copolymer of vinylpyridine and acrylic acid-based free acid, alkylvinylpyridine and acrylic acid-based Copolymer with free acid, copolymer of vinylpyridine and acrylic acid-based free acid and vinyl monomer, copolymer of alkylvinylpyridine and acrylic acid-based free acid and vinyl monomer, 2-methyl-5-vinylpyridine-methacrylic acid copolymer, Poly-2- (vinylphenyl) glycine, morpholino-N- ⁇ -ethylacrylate-methacrylic acid copolymer, shelac, cellulose acetate phthalate, methylacrylate-methacrylic acid copolymer, methylmethacrylate-methacrylic acid copo
- the coating agent may be used in combination with a plasticizer.
- Plasticizers include acetyltributyl citrate, acetyltriethyl citrate, castor oil, diacetylated monoglyceride, dibutyl sebacate, sorbitol, dextrin, diethyl phthalate, glycerin, polyalkylene glycol, polyethylene glycol monoethyl ether, propylene glycol, benzo Examples thereof include benzyl acid acid, purified water, sorbitol sorbitan solution, triacetin, tributyl citrate, triethyl citrate, chlorobutanol and the like. Of these plasticizers, polyalkylene glycol is preferably used, and polyethylene glycol (macrogol) is more preferable. One of these plasticizers may be used alone, or two or more of these plasticizers may be used in combination.
- the components constituting the coating layer may be used as they are, but may be dissolved in water, alcohol, etc., if necessary.
- the amount of the coating layer in the pharmaceutical preparation of the present invention is not particularly limited as long as the pharmaceutical preparation of the present invention exerts a desired effect, but as a mass ratio to the total mass of the nuclear particles (mass of the coating layer: total mass of the nuclear particles).
- the lower limit is preferably 0.001: 1, more preferably 0.002: 1.
- the upper limit is not particularly limited, but is preferably 0.1: 1, more preferably 0.05: 1, and even more preferably 0.02: 1.
- the range of the mass ratio of the coating layer to the total mass of the nuclear particles is not particularly limited, but is preferably 0.001: 1 to 0.1: 1, more preferably 0.002: 1 to 0.05: 1. , Even more preferably 0.002: 1 to 0.02: 1.
- the pharmaceutical preparation of the present invention may contain a pharmaceutically acceptable additive different from the components constituting the nuclear particles and the coating layer described above, as long as the effects of the present invention are not impaired.
- the additive include excipients, disintegrants, lubricants, binders, fluidizers, sweeteners, flavors, colorants and the like. These additives may have one component having two or more functions. In addition, these additives may be used alone or in combination of two or more.
- the pharmaceutical preparation of the present invention includes a coating layer that coats the nuclear particles, leakage of the surfactant and the drug contained in the nuclear particles from the pharmaceutical preparation is suppressed, and as a result, aggregation of the pharmaceutical preparation is suppressed. Can be done.
- the degree of cohesion of the pharmaceutical preparation is preferably 70% or less, more preferably 60% or less, and even more preferably 50% or less.
- the degree of cohesion of the pharmaceutical preparation can be measured by the same method as the above-mentioned measurement of the degree of cohesion of nuclear particles.
- the degree of cohesion of the pharmaceutical preparation is improved (lower) than the degree of cohesion of the nuclear particles.
- the particle size of the pharmaceutical preparation is not particularly limited, but preferably the 50% particle size (D50) based on the volume distribution is 100 to 400 ⁇ m, and more preferably 120 to 250 ⁇ m.
- the measurement of the 50% particle size (D50) based on the volume distribution of the pharmaceutical preparation can be performed by the same method as the measurement of the 50% particle size (D50) based on the volume distribution of the nuclear particle component described above.
- the pharmaceutical preparation of the present invention may be used as it is, or may be used as a preparation having various dosage forms.
- the dosage form of the preparation is not particularly limited as long as the effects of the present invention are exhibited, and examples thereof include granules, tablets, pills, capsules, and powders. Of these, granules, tablets and capsules are preferred. Further, examples of the capsule include a hard capsule.
- the method for producing the pharmaceutical preparation of the present invention is not particularly limited, and a known method can be used.
- the conditions for producing a pharmaceutical preparation can be appropriately adjusted depending on the types of nuclear particle components, surfactants, drugs, coating layer components, and the like.
- the drug the drug represented by the above-mentioned general formula (I) is used.
- the pharmaceutical preparation of the present invention can be produced, for example, according to the following procedure. First, a fluidized bed of a first nuclear particle component, which is acicular and / or substantially columnar crystalline cellulose, and a second nuclear particle component, which is a substantially spherical at least one pharmaceutically acceptable additive.
- a nuclear particle mixture for example, FD-MP-01D, manufactured by Paulec Co., Ltd.
- a drug is added to the surfactant and stirred using a stirrer (NZ-1200, manufactured by Tokyo Rika Kikai Co., Ltd.) to obtain a mixed solution (drug solution) in which the drug is dissolved or suspended.
- a stirrer NZ-1200, manufactured by Tokyo Rika Kikai Co., Ltd.
- the obtained mixture and the mixed solution are brought into contact with each other using a fluidized bed granulator, and the mixed solution is adhered to the nuclear particles in the mixture to obtain nuclear particles.
- the contact between the mixture and the mixed solution is performed, for example, by a method of spraying the mixed solution onto the mixture, a method of immersing the mixed solution in the mixed solution, or the like.
- the nuclear particle component is dried if necessary, and then the nuclear particle is coated with a component (coating layer component) constituting the coating layer.
- the coating of the nuclear particles is performed, for example, by a method of spraying the coating layer component on the nucleus, a method of immersing the nuclear particles in the coating layer component, or the like.
- the particles having the nuclear particles and the coating layer covering the nuclear particles are dried to obtain a pharmaceutical preparation.
- the method for tableting a pharmaceutical preparation is not particularly limited, and a known method can be used.
- the conditions for tableting are not particularly limited, and can be appropriately adjusted depending on the types of nuclear particle components, surfactants, drugs, coating layer components, and the like.
- Examples of the method for tableting and molding a pharmaceutical preparation include a method of locking a pharmaceutical preparation using a locking machine such as a rotary locking machine or a single-shot locking machine. Of these, it is preferable to tablet-mold the pharmaceutical preparation using a rotary locking machine.
- the rotary locking machine include VIRGO 0512SS2AY manufactured by Kikusui Seisakusho Co., Ltd.
- the pharmaceutical preparation of the present invention and the pharmaceutically acceptable additive are mixed in advance and then tableted.
- the method for mixing the pharmaceutical preparation and the additive is not particularly limited, and a known method can be used.
- Examples of the method of mixing the pharmaceutical preparation and the additive include a method of mixing using a mixer such as a V-type mixer. Specifically, mixing can be performed using a V-type mixer (TCV-20) manufactured by Tokuju Kosakusho Co., Ltd.
- the method of using a pharmaceutical preparation as a capsule is not particularly limited, and a known method can be used. Specifically, it is produced by filling a capsule film made of gelatin, a plant-derived raw material, or the like with a pharmaceutical preparation.
- the filling of the capsule film is not particularly limited, and can be performed by a known method such as auger type powder filling, radish press type powder filling, and vibration type powder filling.
- auger-type powder filling a pharmaceutical preparation of powder or granules that is dropped and supplied from a hopper into a cap-shaped body that is usually formed of a gelatin film and has open ends is directly encapsulated by a stirring blade and the rotational pressure of the auger.
- Capsules can be produced by partially filling the capsules in a predetermined amount and then coaxially bonding the bodies.
- average particle size (D50) means “50% particle size based on volume distribution”.
- FIG. 1A and 1B are electron micrographs of needle-shaped and / or substantially columnar crystalline cellulose CEOLUS KG-1000 and CEOLUS UF-702, respectively, and FIG. 2 is an electron micrograph of lactose hydrate (substantially spherical particles). Yes, FIG. 3 is an electron micrograph of corn starch (approximately spherical particles).
- lactose hydrate (SuperTab®, average aspect ratio 1.39, average particle size (D50) 120 ⁇ m, manufactured by DFE Pharma), and corn starch (Japanese corn starch) as substantially spherical particles.
- the average aspect ratio of each nuclear particle component is the aspect ratio of 10 arbitrarily selected particles measured by acquiring a particle image using an electron microscope (VE-7800, manufactured by KEYENCE) and analyzing the image. It means the average value of the aspect ratios of the particles measured and excluding the values of the aspect ratios of the particles having the upper 10% and the lower 10% of the aspect ratio values. Further, in Table 1, unless otherwise specified, the unit of the numerical value is g (gram).
- each surfactant was put into a 500 mL beaker, and stirred and mixed at 400 to 900 rpm using a stirrer (NZ-1200, manufactured by Tokyo Rika Kikai Co., Ltd.). After stirring and mixing until uniform, each drug was added, and the mixture was further stirred and mixed to obtain a drug solution.
- a stirrer NZ-1200, manufactured by Tokyo Rika Kikai Co., Ltd.
- each coating layer component is put into a stainless steel container, and the coating layer solution is prepared by stirring and mixing at 400 to 900 rpm using a stirrer (NZ-1200, manufactured by Tokyo Rika Kikai Co., Ltd.). Obtained.
- the coating layer solution was sprayed on each of the core particles obtained above, dried at 60 ° C. for 15 minutes, and the core particles were dried. Obtained a pharmaceutical formulation coated with a coating layer solution.
- the setting conditions of the fluidized bed granulator are as shown in Table 4.
- the degree of cohesion of the obtained pharmaceutical preparations of Examples 1 and 2 and Comparative Example 1 was measured by the same method as the above-mentioned measurement of the degree of cohesion of nuclear particles. The results are shown in Table 3 above.
- the pharmaceutical preparation could be produced in the form of granules, and tablets could be produced by tableting.
- the pharmaceutical preparation could be produced in the form of granules, and tablets could be produced by tableting.
- the composition of the first and second nuclear particle components of Examples 1 to 3 was changed to set the ratio of D50 of the first nuclear particle component to D50 of the second nuclear particle component to 1: 1.1. It has been confirmed that even when a pharmaceutical preparation is produced by prescription, the aggregation of the pharmaceutical preparation is suppressed and the fluidity is good.
- a pharmaceutical preparation containing a therapeutically effective amount of a poorly water-soluble drug (CDK9 inhibitor) and having excellent fluidity that can withstand actual production.
- CDK9 inhibitor a poorly water-soluble drug
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[1]核粒子と該核粒子を被覆する被覆層とを備える顆粒の形態の医薬製剤であって、
前記核粒子が、薬物、第1の核粒子成分、第2の核粒子成分および界面活性剤を含んでなり、
前記薬物は、下記一般式(I)
で表されるアニリン誘導体もしくはその薬学的に許容可能な塩、またはそれらの水和物であり、
前記第1の核粒子成分は、針状および略柱状から選択される形状を有する少なくとも1種の結晶セルロースであり、
前記第2の核粒子成分は、略球状の少なくとも1種の薬学的に許容可能な添加剤である、前記医薬製剤。
[2]前記薬物が、下記式(I-a)
[3]前記第1の核粒子成分の平均アスペクト比が1.8以上である、[1]または[2]に記載の医薬製剤。
[4]前記第1の核粒子成分の平均アスペクト比が1.8~10.0である、[3]に記載の医薬製剤。
[5]前記第2の核粒子成分の平均アスペクト比が1.0~1.7である、[1]~[4]のいずれかに記載の医薬製剤。
[6]前記第2の核粒子成分の平均アスペクト比が1.0~1.5である、[5]に記載の医薬製剤。
[7]前記第1の核粒子成分の体積分布基準の50%粒子径(D50)に対する前記第2の核粒子成分の体積分布基準の50%粒子径(D50)の比が1:1.1以下である、[1]~[6]のいずれかに記載の医薬製剤。
[8]前記第1の核粒子成分と第2の核粒子成分との平均アスペクト比の差が0.5以上である、[1]~[7]のいずれかに記載の医薬製剤。
[9]前記第2の核粒子成分が、少なくとも2つの異なる成分からなる、[1]~[8]のいずれかに記載の医薬製剤。
[10]前記第1の核粒子成分と第2の核粒子成分との質量比が1:1~1:10である、[1]~[9]のいずれかに記載の医薬製剤。
[11]前記第1の核粒子成分および第2の核粒子成分の総質量と、前記界面活性剤の質量との質量比が1:0.01~1:0.6である、[1]~[10]のいずれかに記載の医薬製剤。
[12]前記界面活性剤と前記薬物との質量比が1:0.1~1:10である、[1]~[11]のいずれかに記載の医薬製剤。
[13]前記第1の核粒子成分および第2の核粒子成分の総質量と、前記被覆層の質量との質量比が1:0.05~1:0.3である、[1]~[12]のいずれかに記載の医薬製剤。
[14]前記第2の核粒子成分が、糖類および無機化合物からなる群から選択される少なくとも1種の薬学的に許容可能な添加剤である、[1]~[13]のいずれかに記載の医薬製剤。
[15]前記第2の核粒子成分が、ブドウ糖、果糖、乳糖、乳糖水和物、ショ糖、白糖、圧縮糖、精製粉末砂糖、アルギン酸アンモニウム、デンプン、ジャガイモデンプン、コムギデンプン、トウモロコシデンプン、コメデンプン、マンニトール、ソルビトール、リン酸塩、炭酸マグネシウム、酸化マグネシウム、炭酸カルシウム、硫酸カルシウム、デキストレート類、デキストリン、デキストロース、ポリメタクリレート、パルミトステアリン酸グリセリン、イソマルト、ラクチトール、カオリン、ラクチトール、マルチトール、マルトデキストリン、マルトース、トレハロース、キシリトール、アルファー化デンプン、変性アルファー化デンプン、タピオカデンプン、塩化ナトリウムからなる群から選択される少なくとも1つのものである、[1]~[14]のいずれかに記載の医薬製剤。
[16]前記界面活性剤が非イオン性界面活性剤である、[1]~[15]のいずれかに記載の医薬製剤。
[17]前記非イオン性界面活性剤がポリソルベートである、[16]に記載の医薬製剤。
[18]前記被覆層が、水溶性コーティング剤を含む、[1]~[17]のいずれかに記載の医薬製剤。
[19]前記水溶性コーティング剤が、ポリアルキレングリコール、多糖類、およびそれらの誘導体からなる群より選択される少なくとも一つの成分である、[18]に記載の医薬製剤。
[20]前記水溶性コーティング剤が、ポリエチレングリコール、メチルセルロース、ヒドロキシメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メタアクリル酸コポリマー、ビニルピリジンコポリマー、アルキルビニルピリジンコポリマー、アミノセルロース誘導体、ジエチルアミノエチルメタクリレート、ポリビニルアセタールジエチルアミノアセテート、ジメチルアミノエチルメタクリレート-メタクリレートコポリマー、セルロースアセテート-N,N-ジ-n-ブチルヒドロキシルプロピルエーテル、ビニルピリジンとアクリル酸系遊離酸とのコポリマー、アルキルビニルピリジンとアクリル酸系遊離酸とのコポリマー、ビニルピリジンとアクリル酸系遊離酸とビニルモノマーとのコポリマー、アルキルビニルピリジンとアクリル酸系遊離酸とビニルモノマーとのコポリマー、2-メチル-5-ビニルピリジン-メタクリル酸コポリマー、ポリ-2-(ビニルフェニル)グリシン、モルホリノ-N-β-エチルアクリレート-メタクリル酸コポリマー、シェラック、セルロースアセテートフタレート、メチルアクリレート-メタクリル酸コポリマー、メチルメタクリレート-メタクリル酸コポリマー、ゼイン、ヒドロキシプロピルメチルセルロースフタレートおよびアミノアルキルメタクリレートコポリマーからなる群から選択される少なくとも1種である、[18]または[19]に記載の医薬製剤。
[21]前記医薬製剤の凝集度が70%以下である、[1]~[20]のいずれかに記載の医薬製剤。
[22]前記医薬製剤の凝集度が前記核粒子の凝集度よりも低い、[1]~[21]のいずれかに記載の医薬製剤。
[23]前記医薬製剤の体積分布基準の50%粒子径(D50)が100~400μmである、[1]~[22]のいずれかに記載の医薬製剤。
[24][1]~[23]のいずれかに記載の医薬製剤を含んでなり、顆粒剤、錠剤、カプセル剤、散剤および丸剤からなる群から選択される剤形を有する製剤。
[25]核粒子と該核粒子を被覆する被覆層とを備える顆粒の形態の医薬製剤の製造方法であって、
(a)第1の核粒子成分と、第2の核粒子成分とを混合して核粒子混合物を得る工程、
(b)界面活性剤と溶媒との混合物に薬物を溶解または懸濁して混合液を得る工程、
(c)工程(a)で得られた核粒子混合物と、工程(b)で得られた混合液とを接触させて第1の核粒子成分、第2の核粒子成分、薬物および界面活性剤を含む核粒子を得る工程、および、
(d)工程(c)で得られた核粒子を被覆して医薬製剤を得る工程
を含み、
前記薬物は、下記一般式(I)
で表されるアニリン誘導体もしくはその薬学的に許容可能な塩、またはそれらの水和物であり、
前記第1の核粒子成分は、針状および略柱状から選択される形状を有する少なくとも1種の結晶セルロースであり、
前記第2の核粒子成分は、略球状の少なくとも1種の薬学的に許容可能な添加剤である、前記製造方法。
[26]前記薬物が、下記式(I-a)
[27]前記第1の核粒子成分の平均アスペクト比が1.8以上である、[25]または[26]に記載の製造方法。
[28]前記第1の核粒子成分の平均アスペクト比が1.8~10.0である、[27]に記載の製造方法。
[29]前記第2の核粒子成分の平均アスペクト比が1.0~1.7である、[25]~[28]のいずれかに記載の製造方法。
[30]前記第2の核粒子成分の平均アスペクト比が1.0~1.5である、[29]に記載の製造方法。
[31]前記第1の核粒子成分の体積分布基準の50%粒子径(D50)に対する前記第2の核粒子成分の体積分布基準の50%粒子径(D50)の比が1:1.1以下である、[25]~[30]のいずれかに記載の製造方法。
[32]前記第2の核粒子成分が、少なくとも2つの異なる成分からなる、[25]~[31]のいずれかに記載の製造方法。
[33](e)工程(d)で得られた医薬製剤に薬学的に許容可能な添加剤を加えて造粒して、顆粒状の製剤を得る工程をさらに含む、[25]~[32]のいずれかに記載の製造方法。
[34](e’)工程(d)で得られた医薬製剤を、ゼラチン、または植物由来の原料からなる皮膜に封入して、カプセル状の製剤を得る工程をさらに含む、[25]~[32]のいずれかに記載の製造方法。
[35][1]~[23]のいずれかに記載の医薬製剤を打錠成形して錠剤を得る工程を含む、錠剤の製造方法。
[36][1]~[23]のいずれか一項に記載の医薬製剤をカプセルに封入する工程を含んでなる、カプセル剤の製造方法。
本発明の医薬製剤は、核粒子と該核粒子を被覆する被覆層とを備える顆粒の形態の医薬製剤である。以下、核粒子および被覆層のそれぞれについて説明する。
核粒子は、薬物、第1の核粒子成分、第2の核粒子成分および界面活性剤を含んでなり、第1の核粒子成分は針状および/または略柱状の結晶セルロース(以下、単に「針状結晶セルロース」という場合がある。)であり、第2の核粒子成分は略球状を有する少なくとも1種の薬学的に許容可能な添加剤である。
本発明の一実施態様によれば、核粒子に使用される第1の核粒子成分は、針状結晶セルロースである。本発明で用いられる第1の核粒子成分である針状結晶セルロースは、医薬製剤の調製において添加され得る結晶セルロースに由来する。針状結晶セルロースとしては、本発明の効果が奏されるのに十分な割合の針状および/または略柱状の結晶を含んでいればよい。第1の核粒子成分における針状および/または略柱状の結晶セルロースの割合の下限値は、特に限定されないが、結晶(粒子)の個数として、好ましくは60%、より好ましくは70%、より一層好ましくは80%である。また、上限値は、例えば、100%、98%、95%、90%等とすることができる。第1の核粒子成分における針状および/または略柱状の結晶セルロースの割合の範囲は、特に限定されないが、結晶(粒子)の個数として、好ましくは60~100%、より好ましくは70~100%、より一層好ましくは80~100%である。本明細書において「針状結晶セルロース」とは、電子顕微鏡により測定される画像上(平面に転写された形状)の結晶セルロースの長軸方向の断面において、縦横の長さに顕著な差がある結晶セルロースをいう。ここで、縦横の長さに顕著な差は、例えば、アスペクト比で表すことができる。
本発明の一実施態様によれば、核粒子に使用される第2の核粒子成分は、略球状の薬学的に許容可能な添加剤である。本明細書において「略球状」とは、電子顕微鏡により測定される画像上(平面に転写された形状)において、縦横の長さに顕著な差が無い球状に近似する形状をいい、針状および略柱状を含まない。したがって、一つの実施態様によれば、第2の核粒子成分は非針状かつ非柱状の薬学的に許容可能な添加剤である。「略球状」は、電子顕微鏡により測定される画像が必ずしも完全な球状そのものである必要はなく、例えば、歪んだ球状、楕円体状、多面体状(立方体状を含む)、角が取れた多面体状であってもよい。
本発明の医薬製剤は、核粒子中において、薬物をその中に溶解または懸濁し得る界面活性剤を含む。界面活性剤としては、薬学的に許容可能なものである限り特に限定されないが、例えば、陽イオン性界面活性剤、陰イオン性界面活性剤、両性界面活性剤、非イオン性界面活性剤等を用いることができる。陽イオン性界面活性剤としては、例えば、第1級アミン塩、アルキルトリメチルアンモニウム塩、アルキルピリジニウム塩、アルキルポリオキシエチレンアミン等が挙げられる。陰イオン性界面活性剤としては、例えば、脂肪酸塩、ロジン酸塩、硫酸アルキルポリオキシエチレン塩、α-オレフィンスルホン酸塩、アルキルナフタレンスルホン酸塩、リグニンスルホン酸塩、リン酸アルキル塩等が挙げられる。両性界面活性剤としては、例えば、N-アルキルβ-アミノプロピオン酸、N-アルキルスルホベタイン、N-アルキルヒドロキシスルホベタイン、レシチン等が挙げられる。非イオン性界面活性剤としては、アルキルポリオキシエチレンエーテル、ポリオキシエチレン脂肪酸エステル、ソルビタン脂肪酸エステル、ショ糖脂肪酸エステル、ポリグリセリン脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル等が挙げられる。これらのうち、界面活性剤は、好ましくは非イオン性界面活性剤、より好ましくはポリソルベート、より一層好ましくはポリソルベート80である。これらの界面活性剤は、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。また、界面活性剤は、例えば、水、アルコール等に溶解させて用いてもよい。
本発明の医薬製剤は、核中に、下記一般式(I)
で表されるアニリン誘導体もしくはその薬学的に許容可能な塩、またはそれらの水和物含んでなる。薬物は、上述した界面活性剤中に溶解または懸濁した状態(以下、「混合液」という場合がある。)で存在することが好ましい。なお、本明細書において「溶媒または懸濁」とは、薬物の一部が溶解し、他の一部が懸濁している状態も包含する。
篩目開き:(上段)710μm、(中段)355μm、(下段)250μm
試料採取量:2gまたは3g
振動時間:119秒
X=[上段の篩に残った粉体質量]/投入した粉体質量×100
Y=[中段の篩に残った粉体質量]/投入した粉体質量×100×0.6
Z=[下段の篩に残った粉体質量]/投入した粉体質量×100×0.2
上記X、Y、Zの3つの値の合計をもって、凝集度(%)とする。
被覆層は、核粒子を被覆して、核粒子に含まれる界面活性剤や薬物が医薬製剤の表面に漏出することを抑制することができる。被覆層により界面活性剤の漏出が抑制される結果、医薬製剤の凝集が抑制され、医薬製剤の流動性の低下を抑制することができる。
本発明の医薬製剤は、本発明の効果を妨げない限り、上述した核粒子および被覆層を構成する成分とは異なる薬学的に許容可能な添加剤を含んでいてもよい。添加物としては、例えば、賦形剤、崩壊剤、滑沢剤、結合剤、流動化剤、甘味料、香料、着色料等が挙げられる。これらの添加物は、1つの成分が2つ以上の機能を担うものであってもよい。また、これらの添加剤は、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。
本発明の医薬製剤の製造方法は、特に限定されず、公知の方法を用いることができる。医薬製剤の製造における条件は、核粒子成分、界面活性剤、薬物、被覆層成分の種類等により、適宜調整することができる。薬物としては、上述した一般式(I)で表される薬物が用いられる。具体的には、本発明の医薬製剤は、例えば、以下の手順に従って製造することができる。まず、針状および/または略柱状の結晶セルロースである第1の核粒子成分と、略球状の少なくとも1種の薬学的に許容可能な添加剤である第2の核粒子成分とを、流動層造粒機(例えば、FD-MP-01D、株式会社パウレック製)を用いて混合して、核粒子混合物(一次粒子)を得る。一方で、界面活性剤に薬物を添加して、撹拌機(NZ-1200、東京理化器械株式会社製)を用いて撹拌して、薬物が溶解または懸濁した混合液(薬物液)を得る。次いで、得られた混合物と混合液とを流動層造粒機を用いて接触させて、混合物中の核粒子に混合液を付着させて核粒子を得る。ここで、混合物と混合液との接触は、例えば、混合液を混合物に噴霧する方法、混合液中に混合物を浸漬する方法等により行われる。次いで、核粒子成分を必要に応じて乾燥させた後、被覆層を構成する成分(被覆層成分)で核粒子を被覆する。ここで、核粒子の被覆は、例えば、被覆層成分を核に噴霧する方法、被覆層成分中に核粒子を浸漬する方法等により行われる。次いで、核粒子と該核粒子を被覆する被覆層とを有する粒子を乾燥させて、医薬製剤を得る。
略球状粒子として、乳糖水和物(SuperTab(登録商標)、平均粒子径(D50)120μm、DFE Pharma製)、およびトウモロコシデンプン(局方コーンスターチ、平均粒子径(D50)15μm、日本食品化工株式会社製)、針状および/または略柱状の結晶セルロースとして、結晶セルロース(CEOLUS UF-702、平均粒子径(D50)140μm、旭化成株式会社製)、および結晶セルロース(CEOLUS KG-1000、平均粒子径(D50)80μm、旭化成株式会社製)を準備し、電子顕微鏡(VE-7800、KEYENCE製)によって画像測定を行った。図1AおよびBは、それぞれ針状および/または略柱状の結晶セルロースCEOLUS KG-1000およびCEOLUS UF-702の電子顕微鏡写真であり、図2は乳糖水和物(略球状粒子)の電子顕微鏡写真であり、図3はトウモロコシデンプン(略球状粒子)の電子顕微鏡写真である
比較例1、実施例1および2の処方で得られたそれぞれの核粒子混合物(一次粒子)について、かためかさ密度およびゆるみかさ密度を測定した。具体的には、パウダテスタ(登録商標)PT-R(ホソカワミクロン株式会社製)を用いて、第17改正日本薬局方に記載されている、かさ密度およびタップ密度測定法第3法の測定用容器と同サイズの円筒容器に核粒子混合物を篩いを通して上方から均一に供給し、上面をすり切って秤量することによって疎充填の状態のかさ密度(ゆるみかさ密度)を測定。次いで、この容器の上に補助円筒をはめ、この上縁まで核粒子混合物を加えてタッピングを180回行ない、終了後、補助円筒を外して容器の上面で核粒子混合物をすり切って秤量し、タッピング後の密充填した場合のかさ密度(かためかさ密度)を測定した。さらに、各核粒子混合物について、かためかさ密度とゆるみかさ密度の差(かためかさ密度-ゆるみかさ密度)を算出した。結果を表3に示す。また、実施例3の処方で得られた核粒子混合物(一次粒子)について、同様の方法によりかためかさ密度およびゆるみかさ密度を測定した。実施例3の核粒子混合物のかためかさ密度とゆるみかさ密度の差(かためかさ密度-ゆるみかさ密度)は0.221であった。
得られた実施例1および2、および比較例の医薬製剤の核粒子について、粉体特性評価装置(パウダテスタ(登録商標)PT-R、ホソカワミクロン株式会社製)を用いて凝集度を測定した。粉体特性評価装置の設定条件は以下の通りとした。
篩目開き:(上段)710μm、(中段)355μm、(下段)250μm
試料採取量:2gまたは3g
振動時間:119秒
X=[上段の篩に残った粉体質量]/投入した粉体質量×100
Y=[中段の篩に残った粉体質量]/投入した粉体質量×100×0.6
Z=[下段の篩に残った粉体質量]/投入した粉体質量×100×0.2
上記X、Y、Zの3つの値の合計をもって、凝集度(%)とした。結果を上記表3に示す。
Claims (36)
- 前記第1の核粒子成分の平均アスペクト比が1.8以上である、請求項1または2に記載の医薬製剤。
- 前記第1の核粒子成分の平均アスペクト比が1.8~10.0である、請求項3に記載の医薬製剤。
- 前記第2の核粒子成分の平均アスペクト比が1.0~1.7である、請求項1~4のいずれか一項に記載の医薬製剤。
- 前記第2の核粒子成分の平均アスペクト比が1.0~1.5である、請求項5に記載の医薬製剤。
- 前記第1の核粒子成分の体積分布基準の50%粒子径(D50)に対する前記第2の核粒子成分の体積分布基準の50%粒子径(D50)の比が1:1.1以下である、請求項1~6のいずれか一項に記載の医薬製剤。
- 前記第1の核粒子成分と第2の核粒子成分との平均アスペクト比の差が0.5以上である、請求項1~7のいずれか一項に記載の医薬製剤。
- 前記第2の核粒子成分が、少なくとも2つの異なる成分からなる、請求項1~8のいずれか一項に記載の医薬製剤。
- 前記第1の核粒子成分と第2の核粒子成分との質量比が1:1~1:10である、請求項1~9のいずれか一項に記載の医薬製剤。
- 前記第1の核粒子成分および第2の核粒子成分の総質量と、前記界面活性剤の質量との質量比が1:0.01~1:0.6である、請求項1~10のいずれか一項に記載の医薬製剤。
- 前記界面活性剤と前記薬物との質量比が1:0.1~1:10である、請求項1~11のいずれか一項に記載の医薬製剤。
- 前記第1の核粒子成分および第2の核粒子成分の総質量と、前記被覆層の質量との質量比が1:0.05~1:0.3である、請求項1~12のいずれか一項に記載の医薬製剤。
- 前記第2の核粒子成分が、糖類および無機化合物からなる群から選択される少なくとも1種の薬学的に許容可能な添加剤である、請求項1~13のいずれか一項に記載の医薬製剤。
- 前記第2の核粒子成分が、ブドウ糖、果糖、乳糖、乳糖水和物、ショ糖、白糖、圧縮糖、精製粉末砂糖、アルギン酸アンモニウム、デンプン、ジャガイモデンプン、コムギデンプン、トウモロコシデンプン、コメデンプン、マンニトール、ソルビトール、リン酸塩、炭酸マグネシウム、酸化マグネシウム、炭酸カルシウム、硫酸カルシウム、デキストレート類、デキストリン、デキストロース、ポリメタクリレート、パルミトステアリン酸グリセリン、イソマルト、ラクチトール、カオリン、ラクチトール、マルチトール、マルトデキストリン、マルトース、トレハロース、キシリトール、アルファー化デンプン、変性アルファー化デンプン、タピオカデンプン、塩化ナトリウムからなる群から選択される少なくとも1つのものである、請求項1~14のいずれか一項に記載の医薬製剤。
- 前記界面活性剤が非イオン性界面活性剤である、請求項1~15のいずれか一項に記載の医薬製剤。
- 前記非イオン性界面活性剤がポリソルベートである、請求項16に記載の医薬製剤。
- 前記被覆層が、水溶性コーティング剤を含む、請求項1~17のいずれか一項に記載の医薬製剤。
- 前記水溶性コーティング剤が、ポリアルキレングリコール、多糖類、およびそれらの誘導体からなる群より選択される少なくとも一つの成分である、請求項18に記載の医薬製剤。
- 前記水溶性コーティング剤が、ポリエチレングリコール、メチルセルロース、ヒドロキシメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メタアクリル酸コポリマー、ビニルピリジンコポリマー、アルキルビニルピリジンコポリマー、アミノセルロース誘導体、ジエチルアミノエチルメタクリレート、ポリビニルアセタールジエチルアミノアセテート、ジメチルアミノエチルメタクリレート-メタクリレートコポリマー、セルロースアセテート-N,N-ジ-n-ブチルヒドロキシルプロピルエーテル、ビニルピリジンとアクリル酸系遊離酸とのコポリマー、アルキルビニルピリジンとアクリル酸系遊離酸とのコポリマー、ビニルピリジンとアクリル酸系遊離酸とビニルモノマーとのコポリマー、アルキルビニルピリジンとアクリル酸系遊離酸とビニルモノマーとのコポリマー、2-メチル-5-ビニルピリジン-メタクリル酸コポリマー、ポリ-2-(ビニルフェニル)グリシン、モルホリノ-N-β-エチルアクリレート-メタクリル酸コポリマー、シェラック、セルロースアセテートフタレート、メチルアクリレート-メタクリル酸コポリマー、メチルメタクリレート-メタクリル酸コポリマー、ゼイン、ヒドロキシプロピルメチルセルロースフタレートおよびアミノアルキルメタクリレートコポリマーからなる群から選択される少なくとも1種である、請求項18または19に記載の医薬製剤。
- 前記医薬製剤の凝集度が70%以下である、請求項1~20のいずれか一項に記載の医薬製剤。
- 前記医薬製剤の凝集度が前記核粒子の凝集度よりも低い、請求項1~21のいずれか一項に記載の医薬製剤。
- 前記医薬製剤の体積分布基準の50%粒子径(D50)が100~400μmである、請求項1~22のいずれか一項に記載の医薬製剤。
- 請求項1~23のいずれか一項に記載の医薬製剤を含んでなり、顆粒剤、錠剤、カプセル剤、散剤および丸剤からなる群から選択される剤形を有する製剤。
- 核粒子と該核粒子を被覆する被覆層とを備える顆粒の形態の医薬製剤の製造方法であって、
(a)第1の核粒子成分と、第2の核粒子成分とを混合して核粒子混合物を得る工程、
(b)界面活性剤と溶媒との混合物に薬物を溶解または懸濁して混合液を得る工程、
(c)工程(a)で得られた核粒子混合物と、工程(b)で得られた混合液とを接触させて第1の核粒子成分、第2の核粒子成分、薬物および界面活性剤を含む核粒子を得る工程、および、
(d)工程(c)で得られた核粒子を被覆して医薬製剤を得る工程
を含み、
前記薬物は、下記一般式(I)
で表されるアニリン誘導体もしくはその薬学的に許容可能な塩、またはそれらの水和物であり、
前記第1の核粒子成分は、針状および略柱状から選択される形状を有する少なくとも1種の結晶セルロースであり、
前記第2の核粒子成分は、略球状の少なくとも1種の薬学的に許容可能な添加剤である、前記製造方法。 - 前記第1の核粒子成分の平均アスペクト比が1.8以上である、請求項25または26に記載の製造方法。
- 前記第1の核粒子成分の平均アスペクト比が1.8~10.0である、請求項27に記載の製造方法。
- 前記第2の核粒子成分の平均アスペクト比が1.0~1.7である、請求項25~28のいずれか一項に記載の製造方法。
- 前記第2の核粒子成分の平均アスペクト比が1.0~1.5である、請求項29に記載の製造方法。
- 前記第1の核粒子成分の体積分布基準の50%粒子径(D50)に対する前記第2の核粒子成分の体積分布基準の50%粒子径(D50)の比が1:1.1以下である、請求項25~30のいずれか一項に記載の製造方法。
- 前記第2の核粒子成分が、少なくとも2つの異なる成分からなる、請求項25~31のいずれか一項に記載の製造方法。
- (e)工程(d)で得られた医薬製剤に薬学的に許容可能な添加剤を加えて造粒して、顆粒状の製剤を得る工程をさらに含む、請求項25~32のいずれか一項に記載の製造方法。
- (e’)工程(d)で得られた医薬製剤を、ゼラチン、または植物由来の原料からなる皮膜に封入して、カプセル状の製剤を得る工程をさらに含む、請求項25~32のいずれか一項に記載の製造方法。
- 請求項1~23のいずれか一項に記載の医薬製剤を打錠成形して錠剤を得る工程を含む、錠剤の製造方法。
- 請求項1~23のいずれか一項に記載の医薬製剤をカプセルに封入する工程を含んでなる、カプセル剤の製造方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/605,747 US20220211688A1 (en) | 2019-04-25 | 2020-04-24 | Pharmaceutical preparation and method for producing the same |
EP20794267.3A EP3960240B1 (en) | 2019-04-25 | 2020-04-24 | Pharmaceutical preparation and method for producing same |
JP2021516266A JP7183403B2 (ja) | 2019-04-25 | 2020-04-24 | 医薬製剤およびその製造方法 |
CN202080030978.6A CN114126590B (zh) | 2019-04-25 | 2020-04-24 | 医药制剂及其制造方法 |
KR1020217038479A KR20220030212A (ko) | 2019-04-25 | 2020-04-24 | 의약 제제 및 그 제조 방법 |
BR112021021232A BR112021021232A2 (pt) | 2019-04-25 | 2020-04-24 | Preparação farmacêutica na forma de grânulos, preparação, método de produção de uma preparação farmacêutica e métodos para a produção de comprimidos e para a produção de cápsulas |
ZA2021/08670A ZA202108670B (en) | 2019-04-25 | 2021-11-05 | Pharmaceutical preparation and method for producing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-084695 | 2019-04-25 | ||
JP2019084695 | 2019-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020218518A1 true WO2020218518A1 (ja) | 2020-10-29 |
Family
ID=72942137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/017711 WO2020218518A1 (ja) | 2019-04-25 | 2020-04-24 | 医薬製剤およびその製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220211688A1 (ja) |
EP (1) | EP3960240B1 (ja) |
JP (1) | JP7183403B2 (ja) |
KR (1) | KR20220030212A (ja) |
CN (1) | CN114126590B (ja) |
BR (1) | BR112021021232A2 (ja) |
TW (1) | TWI829920B (ja) |
WO (1) | WO2020218518A1 (ja) |
ZA (1) | ZA202108670B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022091442A1 (ja) * | 2020-10-28 | 2022-05-05 | 株式会社キノファーマ | ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物 |
WO2023214568A1 (ja) * | 2022-05-02 | 2023-11-09 | 株式会社キノファーマ | アニリン誘導体を含有する皮膚用外用剤 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508386A (ja) | 1999-08-30 | 2003-03-04 | シエーリング アクチエンゲゼルシャフト | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
JP2007517062A (ja) | 2003-12-29 | 2007-06-28 | アルザ・コーポレーシヨン | 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング |
WO2009020198A1 (ja) * | 2007-08-03 | 2009-02-12 | Kinopharma, Inc. | 抗dnaウイルス作用を有するアニリン誘導体 |
WO2010095494A1 (ja) * | 2009-02-19 | 2010-08-26 | アサヒビール株式会社 | 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法 |
JP2015048315A (ja) * | 2013-08-30 | 2015-03-16 | 旭化成ケミカルズ株式会社 | セルロース系核粒子及びその製造方法 |
JP2019084695A (ja) | 2017-11-02 | 2019-06-06 | キヤノンファインテックニスカ株式会社 | 記録装置 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100526285B1 (ko) * | 2000-11-06 | 2005-11-08 | 아사히 가세이 가부시키가이샤 | 약제 제제용 셀룰로오스계 입자 |
JP2004339162A (ja) * | 2003-05-16 | 2004-12-02 | Shin Etsu Chem Co Ltd | 難溶性薬物を含む医薬用固形製剤とその製造方法 |
JP2006016329A (ja) * | 2004-06-30 | 2006-01-19 | Lion Corp | 粒状医薬品 |
JP4342426B2 (ja) * | 2004-11-24 | 2009-10-14 | 科研製薬株式会社 | イトラコナゾール経口投与用製剤 |
WO2010038688A1 (ja) * | 2008-09-30 | 2010-04-08 | アステラス製薬株式会社 | アトルバスタチン経口投与用粒子状医薬組成物 |
EP3686290B1 (en) * | 2014-04-04 | 2023-08-23 | Memorial Sloan-Kettering Cancer Center | Method and kits for identifying cdk9 inhibitors for the treatment of cancer |
-
2020
- 2020-04-24 KR KR1020217038479A patent/KR20220030212A/ko not_active Application Discontinuation
- 2020-04-24 CN CN202080030978.6A patent/CN114126590B/zh active Active
- 2020-04-24 JP JP2021516266A patent/JP7183403B2/ja active Active
- 2020-04-24 TW TW109113838A patent/TWI829920B/zh active
- 2020-04-24 US US17/605,747 patent/US20220211688A1/en active Pending
- 2020-04-24 WO PCT/JP2020/017711 patent/WO2020218518A1/ja active Search and Examination
- 2020-04-24 EP EP20794267.3A patent/EP3960240B1/en active Active
- 2020-04-24 BR BR112021021232A patent/BR112021021232A2/pt unknown
-
2021
- 2021-11-05 ZA ZA2021/08670A patent/ZA202108670B/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508386A (ja) | 1999-08-30 | 2003-03-04 | シエーリング アクチエンゲゼルシャフト | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
JP2007517062A (ja) | 2003-12-29 | 2007-06-28 | アルザ・コーポレーシヨン | 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング |
WO2009020198A1 (ja) * | 2007-08-03 | 2009-02-12 | Kinopharma, Inc. | 抗dnaウイルス作用を有するアニリン誘導体 |
WO2010095494A1 (ja) * | 2009-02-19 | 2010-08-26 | アサヒビール株式会社 | 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法 |
JP2015048315A (ja) * | 2013-08-30 | 2015-03-16 | 旭化成ケミカルズ株式会社 | セルロース系核粒子及びその製造方法 |
JP2019084695A (ja) | 2017-11-02 | 2019-06-06 | キヤノンファインテックニスカ株式会社 | 記録装置 |
Non-Patent Citations (4)
Title |
---|
AJIRO, CLIN CANCER RES., vol. 24, no. 18, 30 April 2018 (2018-04-30), pages 4518 - 4528 |
OKAMOTO, ANTIVIRAL RES, vol. 123, 21 August 2015 (2015-08-21), pages 1 - 4 |
TANAKA, ANTIVIRAL RES, vol. 133, 8 August 2016 (2016-08-08), pages 156 - 64 |
YAMAMOTO, J CLIN INVEST, vol. 124, no. 8, 8 July 2014 (2014-07-08), pages 3479 - 88 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022091442A1 (ja) * | 2020-10-28 | 2022-05-05 | 株式会社キノファーマ | ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物 |
WO2023214568A1 (ja) * | 2022-05-02 | 2023-11-09 | 株式会社キノファーマ | アニリン誘導体を含有する皮膚用外用剤 |
JP7406778B1 (ja) * | 2022-05-02 | 2023-12-28 | 株式会社キノファーマ | アニリン誘導体を含有する皮膚用外用剤 |
Also Published As
Publication number | Publication date |
---|---|
KR20220030212A (ko) | 2022-03-10 |
EP3960240A1 (en) | 2022-03-02 |
BR112021021232A2 (pt) | 2021-12-21 |
TWI829920B (zh) | 2024-01-21 |
TW202106299A (zh) | 2021-02-16 |
EP3960240A4 (en) | 2023-02-08 |
JP7183403B2 (ja) | 2022-12-05 |
CN114126590A (zh) | 2022-03-01 |
US20220211688A1 (en) | 2022-07-07 |
ZA202108670B (en) | 2023-10-25 |
CN114126590B (zh) | 2024-01-05 |
EP3960240B1 (en) | 2024-03-27 |
JPWO2020218518A1 (ja) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6560289B2 (ja) | 新たな医薬組成物 | |
WO2020218518A1 (ja) | 医薬製剤およびその製造方法 | |
WO2014030204A1 (ja) | 薬物含有中空粒子 | |
JP2007308480A (ja) | 腸溶性固体分散体を含んでなる固形製剤 | |
CZ285199B6 (cs) | Pevný farmaceutický prostředek | |
JP6308938B2 (ja) | 粒状物を製造する方法 | |
TW201818936A (zh) | 一種吡啶酮類衍生物醫藥組成物及其製備方法 | |
JP5442609B2 (ja) | セルロース組成物 | |
WO2020218517A1 (ja) | 医薬製剤およびその製造方法 | |
JP6361925B2 (ja) | 固形製剤 | |
JP2013023463A (ja) | 生理活性物質含有粒子の製造方法 | |
JPWO2020218517A5 (ja) | ||
JP5576922B2 (ja) | 腸溶性固体分散体を含んでなる固形製剤 | |
JP2018530538A5 (ja) | ||
JP5774308B2 (ja) | 水溶性ビノレルビン塩の安定な医薬組成物 | |
JP4494712B2 (ja) | マルチプルユニット型徐放性製剤 | |
JP7133811B2 (ja) | 錠剤 | |
JP7109255B2 (ja) | 粉砕物の製造方法及び錠剤の製造方法 | |
JP2017075138A (ja) | ジエノゲスト含有錠剤 | |
JP2022069437A (ja) | 医薬製剤およびその製造方法 | |
WO2023085300A1 (ja) | 優れた溶出性を有する医薬組成物 | |
CA2671778A1 (en) | Immediate release dosage form of bosentan and process of manufacturing such | |
WO2017064814A1 (ja) | ジエノゲスト含有錠剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20794267 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2021516266 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021021232 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020794267 Country of ref document: EP Effective date: 20211125 |
|
ENP | Entry into the national phase |
Ref document number: 112021021232 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211022 |